Anjana Bose, PhD

Metabolic Effects of Aripiprazole Lauroxil

November 23, 2016

Aripiprazole lauroxil, a long-acting injectable antipsychotic, demonstrated safety and efficacy in treating schizophrenia symptoms in a recent RCT. But how does it stack up against other antipsychotics in terms...

Henry A. Nasrallah, John W. Newcomer, Robert Risinger, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

August 26, 2015

Herbert Y. Meltzer, Robert Risinger, Henry A. Nasrallah, et al

Original Research

Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study

April 15, 2013

Stuart A. Montgomery, Lucilla Mansuy, Adam Ruth, et al

Original Research

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

March 15, 2013

Gregory M. Asnis, Anjana Bose, Carl P. Gommoll, et al

Original Research

Escitalopram Maintenance Treatment for Prevention of Recurrent Depression: A Randomized, Placebo-Controlled Trial

November 15, 2006

Susan G. Kornstein, Anjana Bose, Dayong Li, et al

Original Research

Safety and Efficacy of Escitalopram in the Long-Term Treatment of Generalized Anxiety Disorder

November 15, 2005

Jonathan R. T. Davidson, Anjana Bose, Qin Wang

Original Research

Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes

January 1, 2004

Mark Hyman Rapaport, Anjana Bose, Hongjie Zheng

Original Research

Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients

April 1, 2002

William J. Burke, Ivan Gergel, Anjana Bose

Metabolic Effects of Aripiprazole Lauroxil

A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Escitalopram Maintenance Treatment for Prevention of Recurrent Depression: A Randomized, Placebo-Controlled Trial

Safety and Efficacy of Escitalopram in the Long-Term Treatment of Generalized Anxiety Disorder

Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes

Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients

ELSEWHERE:

FOLLOW US:

Anjana Bose, PhD

Metabolic Effects of Aripiprazole Lauroxil

A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Escitalopram Maintenance Treatment for Prevention of Recurrent Depression: A Randomized, Placebo-Controlled Trial

Safety and Efficacy of Escitalopram in the Long-Term Treatment of Generalized Anxiety Disorder

Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes

Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles